Pfizer
Search results
Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
2 days ago · Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q2 2024 results on Friday, July 26. We expect BMY stock to trade higher, with its revenue and earnings likely exceeding the street...
Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases.
We promote health equity and seek to improve the health outcomes of populations disproportionately affected by serious diseases. Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.
1 day ago · The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into key drug brands and research and development programs.
9 hours ago · Bristol-Myers Squibb (BMY) shows strong Q2 earnings and potential for growth, with a 5% dividend yield and 40% undervaluation despite recent spike.
Jun 21, 2024 · Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
We are a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. We are investing billions in Research and Development (R&D), which includes the discovery and development of new medicines.
1 day ago · Bristol Myers Squibb posted second quarter revenues of $12.2 billion, an increase of 9%, or 11% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and...
